Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 973

The DOI matches its Crossref record.

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

Capeding, Maria Rosario, Tran, Ngoc Huu, Hadinegoro, Sri Rezeki S, Ismail, Hussain Imam HJ Muhammad, Chotpitayasunondh, Tawee, Chua, Mary Noreen, Luong, Chan Quang, Rusmil, Kusnandi, Wirawan, Dewa Nyoman, Nallusamy, Revathy, Pitisuttithum, Punnee, Thisyakorn, Usa, Yoon, In-Kyu, van der Vliet, Diane, Langevin, Edith, Laot, Thelma, Hutagalung, Yanee, Frago, Carina, Boaz, Mark, Wartel, T Anh, Tornieporth, Nadia G, Saville, Melanie, Bouckenooghe, Alain·2014·The Lancet
DOI 10.1016/s0140-6736(14)61060-6
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)61060-6

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 16

  1. Sabchareon, 2012, Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial, Lancet, 380, 1559, 10.1016/S0140-6736(12)61428-7 · DOI · Paper page
  2. Bhatia, 2013, Changing epidemiology of dengue in South-East Asia, WHO-SEAJPH, 2, 23
  3. Messina, 2014, Global spread of dengue virus types: mapping the 70 year history, Trends Microbiol, 22, 138, 10.1016/j.tim.2013.12.011 · DOI · Paper page
  4. Rodríguez-Barraquer, 2014, Revisiting Rayong: shifting seroprofiles of dengue in Thailand and their implications for transmission and control, Am J Epidemiol, 179, 353, 10.1093/aje/kwt256 · doi:10.1093/aje/kwt256
  5. Dayan, 2013, Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA, Vaccine, 31, 5047, 10.1016/j.vaccine.2013.08.088 · DOI
  6. Hss, 2013, Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, phase III study, Vaccine, 31, 5814, 10.1016/j.vaccine.2013.10.013 · doi:10.1016/j.vaccine.2013.10.013
  7. Leo, 2012, Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore, Hum Vaccin Immunother, 8, 1259, 10.4161/hv.21224 · DOI
  8. Lanata, 2012, Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru, Vaccine, 30, 5935, 10.1016/j.vaccine.2012.07.043 · DOI
  9. Tran, 2012, Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children, J Vaccines Vaccin, 3, 1
  10. Guy, 2011, From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine, Vaccine, 29, 7229, 10.1016/j.vaccine.2011.06.094 · DOI · Paper page
  11. Dayan, 2013, Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil, Am J Trop Med Hyg, 89, 1058, 10.4269/ajtmh.13-0304 · doi:10.4269/ajtmh.13-0304
  12. Timiryasova, 2013, Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development, Am J Trop Med Hyg, 88, 962, 10.4269/ajtmh.12-0461 · doi:10.4269/ajtmh.12-0461
  13. Hombach, 2009, Guidelines for clinical trials of dengue vaccine in endemic areas, J Clin Virol, 46, S7, 10.1016/S1386-6532(09)70287-2 · DOI
  14. Shepard, 2013, Economic and disease burden of dengue in Southeast Asia, PLoS Negl Trop Dis, 7, e2055, 10.1371/journal.pntd.0002055 · DOI · Paper page
  15. Sejvar, 2007, Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data, Vaccine, 25, 5771, 10.1016/j.vaccine.2007.04.060 · DOI · Paper page
  16. Huynh, 2008, Post-vaccination encephalomyelitis: literature review and illustrative case, J Clin Neurosci, 15, 1315, 10.1016/j.jocn.2008.05.002 · DOI · Paper page

Cited by

See all 973

Metadata

Authors
Capeding, M. R., Tran, N. H., Hadinegoro, S. R. S., Ismail, H. I. H. M., Chotpitayasunondh, T., Chua, M. N., Luong, C. Q., Rusmil, K., Wirawan, D. N., Nallusamy, R., Pitisuttithum, P., Thisyakorn, U., Yoon, I.-K., van der Vliet, D., Langevin, E., Laot, T., Hutagalung, Y., Frago, C., Boaz, M., Wartel, T. A., Tornieporth, N. G., Saville, M., & Bouckenooghe, A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2014-10
Volume
384
Issue
9951
Pages
1358-1365
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(14)61060-6
OpenAlex
W2116471574
Cited by
973
References
0
FWCI
131.14
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(14)61060-6
The paper
Capeding, M. R., Tran, N. H., Hadinegoro, S. R. S., Ismail, H. I. H. M., Chotpitayasunondh, T., Chua, M. N., Luong, C. Q., Rusmil, K., Wirawan, D. N., Nallusamy, R., Pitisuttithum, P., Thisyakorn, U., Yoon, I.-K., van der Vliet, D., Langevin, E., Laot, T., Hutagalung, Y., Frago, C., Boaz, M., . . . Bouckenooghe, A. (2014). Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(14)61060-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.